Nutrichem(920819)

Search documents
颖泰生物:独立董事关于第四届董事会第一次会议相关事项的独立意见
2023-09-13 08:11
经审阅《关于聘任陈伯阳先生为公司总经理的议案》,全体独立 董事认为,公司董事会对公司总经理聘任的审议和表决程序符合规范, 符合《公司法》《北京证券交易所股票上市规则(试行)》及《公司章 程》等法律法规及规范性文件的规定,不存在损害中小股东利益的情 形。 证券代码:833819 证券简称:颖泰生物 公告编号:2023-053 北京颖泰嘉和生物科技股份有限公司 独立董事关于第四届董事会第一次会议 相关事项的独立意见 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记 载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 作为北京颖泰嘉和生物科技股份有限公司(以下简称"公司") 的独立董事,根据《中华人民共和国公司法》、《北京颖泰嘉和生物科 技股份有限公司章程》等法律法规及规范性文件的规定,我们在第四 届董事会第一次独立董事专门会议上认真审阅了公司第四届董事会 第一次会议相关文件,并就本次会议审议的相关事项,秉承客观公正 的原则,基于独立判断的立场出具如下意见: 一、关于聘任陈伯阳先生为公司总经理的独立意见 经资格审查,刘晓亮先生不属于失信联合惩戒对象,结合其个人 ...
颖泰生物:第四届董事会第一次会议决议公告
2023-09-13 08:11
第四届董事会第一次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记 载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 一、会议召开和出席情况 (一)会议召开情况 证券代码:833819 证券简称:颖泰生物 公告编号:2023-052 北京颖泰嘉和生物科技股份有限公司 1.会议召开时间:2023 年 9 月 12 日 2.会议召开地点:公司会议室 3.会议召开方式:通讯会议 4.发出董事会会议通知的时间和方式:2023 年 9 月 12 日以电话 及口头通知方式发出 5.会议主持人:全体董事共同推举董事王榕先生主持会议 6.会议列席人员:全体监事 7.召开情况合法、合规、合章程性说明: 根据公司《董事会议事规则》第十八条规定:"董事会召开临时 董事会会议原则上以书面形式通过专人送达、传真、电子邮件或者其 他方式通知,通知时限为 2 日;如情况紧急,需要尽快召开董事会临 时会议的,可以随时通过电话、传真、电子邮件或者其他口头方式发 出会议通知,随时召开董事会,但召集人应当在会议上做出说明。" 因 2023 年 9 月 12 日公司 2023 年 ...
颖泰生物:2023年第一次职工代表大会决议公告
2023-09-13 08:11
证券代码:833819 证券简称:颖泰生物 公告编号:2023-055 北京颖泰嘉和生物科技股份有限公司 2023 年第一次职工代表大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假 记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 会议时间:2023 年 9 月 12 日 会议地点:公司会议室 会议主持人:工会主席董鑫 北京颖泰嘉和生物科技股份有限公司(以下简称"公司")2023 年第一次职工代表大会于 2023 年 9 月 12 日在公司会议室召开,出席 本次会议的职工代表应到 30 人,实到 30 人。本次会议的召集、召开 符合《公司法》及《公司章程》的相关规定,会议决议合法有效。 会议内容:鉴于公司第三届监事会任期即将届满,为保障公司监 事会正常运行,公司拟进行监事会换届选举。公司第四届监事会成员 为 3 名,其中:非职工代表监事 2 名,职工代表监事 1 名,任期三年。 其中,职工代表监事由职工代表大会选举产生。 经与会职工代表审议,本次会议以无记名投票的方式对公司工会 委员会的提名的职工代表监事的候选人进行表决,汪春华先生以 25 ...
颖泰生物:董事长、监事会主席、高级管理人员及职工代表监事换届公告
2023-09-13 08:11
证券代码:833819 证券简称:颖泰生物 公告编号:2023-056 北京颖泰嘉和生物科技股份有限公司董事长、监事会主 一、换届基本情况 (一)董事长换届的基本情况 根据《公司法》及公司章程的有关规定,公司第四届董事会第一次会 议于 2023 年 9 月 12 日审议并通过: 选举王榕先生为公司董事长,任职期限三年,自 2023 年 9 月 12 日起 生效。上述选举人员持有公司股份 23,639,000 股,占公司股本的 1.93%, 不是失信联合惩戒对象。 (二)监事会主席换届的基本情况 根据《公司法》及公司章程的有关规定,公司第四届监事会第一次会 议于 2023 年 9 月 12 日审议并通过: 选举王剑先生为公司监事会主席,任职期限三年,自 2023 年 9 月 12 日起生效。上述选举人员持有公司股份 0 股,占公司股本的 0.00%,不是 失信联合惩戒对象。 (三)高级管理人员换届的基本情况 席、高级管理人员及职工代表监事换届公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、误 导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带法律责 任。 根据《公司 ...
颖泰生物:第四届监事会第一次会议决议公告
2023-09-13 08:11
3.会议召开方式:通讯会议 4.发出监事会会议通知的时间和方式:2023 年 9 月 12 日以电话 及口头通知方式发出 证券代码:833819 证券简称:颖泰生物 公告编号:2023-054 北京颖泰嘉和生物科技股份有限公司 第四届监事会第一次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整,没有虚假记 载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 一、会议召开和出席情况 (一)会议召开情况 1.会议召开时间:2023 年 9 月 12 日 2.会议召开地点:公司会议室 5.会议主持人:全体监事共同推举监事王剑先生主持会议 6.召开情况合法、合规、合章程性说明: 根据公司《监事会议事规则》第十条规定:"召开监事会定期会 议和临时会议,监事会办公室应当分别提前十日和二日将盖有监事会 印章的书面会议通知,通过专人送达、传真或者其他方式,提交全体 监事。非专人送达的,还应当通过电话进行确认并做相应记录。如情 况紧急,需要尽快召开监事会临时会议的,可以随时通过电话、传真、 电子邮件或者其他口头方式发出会议通知,随时召开监事会,但召集 人应当在会议上做出说 ...
颖泰生物(833819) - 投资者关系活动记录表
2023-09-06 08:51
证券代码:833819 证券简称:颖泰生物 公告编号:2023-049 北京颖泰嘉和生物科技股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实、准确和完整承担个别及连带责任。 一、投资者关系活动类别 □特定对象调研 业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他(请文字说明其他活动内容) 二、投资者关系活动情况 (一)活动时间、地点 本次 2023 年半年度报告业绩说明会于 2023 年 9 月 5 日(星期 二)15:00-17:00 通过网络方式召开,投资者通过登录全景网"投资 者关系互动平台"(https://ir.p5w.net/)参与了本次 2023 年半年 度报告业绩说明会。 (二)参与单位及人员 通过网络方式参与公司 2023 年半年度报告业绩说明会的投资者。 (三)上市公司接待人员 公司董事长:王榕先生 公司董事会秘书:刘晓亮先生 公司财务负责人:杨玉松先生 公司保荐代表人:孔辉焕先生 三、投资者关系活动主要内容 本次业绩说明会通过半年度报告解读、播放视频宣传片等形式对 公司情 ...
颖泰生物:2023年半年度报告业绩说明会预告公告
2023-08-31 08:37
证券代码:833819 证券简称:颖泰生物 公告编号:2023-048 北京颖泰嘉和生物科技股份有限公司 2023 年半年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、误 导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带法律责 任。 一、 说明会类型 北京颖泰嘉和生物科技股份有限公司(以下简称"公司")于 2023 年 8 月 24 日在北京证券交易所指定信息披露平台 (http://www.bse.cn/)发布了《2023 年半年度报告》(公告编号: 2023-038),为方便广大投资者更深入了解公司 2023 年半年度经营业 绩的具体情况,加强与投资者的互动交流,公司拟召开 2023 年半年 度报告业绩说明会。 本次半年度报告业绩说明会将采用网络方式召开,投资者可登录 全景网"投资者关系互动平台"(https://ir.p5w.net)参与本次半 年度报告业绩说明会。 三、 参加人员 公司董事长: 王榕先生 公司董事会秘书: 刘晓亮先生 公司财务负责人: 杨玉松先生 公司保荐代表人: 孔辉焕先生 四、 投资者参加方式 本次说明会采用网络 ...
颖泰生物(833819) - 2023 Q2 - 季度财报
2023-08-23 16:00
Financial Performance - The company's revenue for the first half of 2023 was approximately ¥2.95 billion, a decrease of 30.93% compared to ¥4.28 billion in the same period last year[25]. - The net profit attributable to shareholders of the listed company was approximately ¥150.13 million, down 78.46% from ¥697.10 million in the previous year[25]. - The gross profit margin decreased to 19.63% from 26.22% year-on-year[25]. - The basic earnings per share fell to ¥0.12, a decline of 78.95% compared to ¥0.57 in the same period last year[25]. - Total operating revenue for the first half of 2023 was CNY 2,954,829,186.08, a decrease of 30.9% compared to CNY 4,278,108,332.05 in the same period of 2022[184]. - Net profit for the first half of 2023 was CNY 146,539,635.29, a decline of 79.1% compared to CNY 700,648,718.35 in the first half of 2022[185]. - The company's investment income decreased by 99.49% to ¥1.77 million, primarily due to the decline in profitability of its joint venture, ALBAUGH[67]. - The company's cash flow from operating activities showed a net outflow of approximately ¥289.42 million, a significant decrease of 163.20% compared to a net inflow of ¥457.93 million in the previous year[73]. Assets and Liabilities - Total assets increased by 1.78% to ¥12,769,980,330.88 compared to the previous year[27]. - Total liabilities rose by 1.62% to ¥6,722,012,780.18 year-over-year[27]. - Net assets attributable to shareholders increased by 2.02% to ¥6,038,712,428.72[27]. - The company's inventory increased by 17.78% to ¥2.13 billion, compared to ¥1.81 billion at the end of the previous year[57]. - Current assets totaled ¥5,556,019,134.03 as of June 30, 2023, down from ¥5,718,413,896.66 at the end of 2022, a decrease of about 2.84%[174]. - Total liabilities increased slightly from ¥6,614,545,392.17 to ¥6,722,012,780.18, an increase of about 1.63%[176]. - Total assets rose from ¥12,546,601,755.66 to ¥12,769,980,330.88, an increase of approximately 1.77%[176]. Research and Development - The company has established a comprehensive R&D system, participating in multiple national key research projects[43]. - Research and development expenses decreased by 12.23% to ¥93.96 million, compared to ¥107.05 million in the previous year[61]. - The company plans to increase R&D investment and optimize personnel structure to maintain its high-tech enterprise status[1]. - Research and development expenses for the first half of 2023 were CNY 93,956,787.89, a decrease of 12.1% compared to CNY 107,052,534.42 in the first half of 2022[184]. Market Presence and Strategy - The company maintains a strong market presence with 1,247 overseas registration certificates, including 195 self-registered[45]. - The company has established a stable customer base through long-term cooperation with globally recognized large agrochemical companies, enhancing its core competitiveness[48]. - The company is focusing on cost control and order delivery while integrating production management, supply chain operations, and market sales to respond to customer needs effectively[51]. - The company plans to enhance its market presence through strategic acquisitions and new product developments in the upcoming fiscal year[93]. Environmental Commitment - The company completed the environmental protection acceptance for its NC106 project, which has an annual production capacity of 1,000 tons, and is currently in trial production[3]. - The company continues to prioritize environmental protection, adhering to pollution control regulations and optimizing processes to reduce energy consumption and emissions[89]. - The company is committed to green and low-toxicity product development, aligning with industry trends towards sustainable and clean production[53]. - The company has implemented a new RTO device, which has shown a reduction in sulfur dioxide emissions to 2.02 g/m³[94]. Governance and Risk Management - Company faced risks related to improper control by major shareholders, holding 47.52% of the shares, and plans to enhance governance structures to mitigate this risk[118]. - The company has established a risk-oriented internal management system to address environmental protection requirements and potential penalties[1]. - The company is committed to improving internal control systems to adapt to its expanding scale and mitigate governance risks[118]. - The company has engaged third-party monitoring agencies to conduct regular assessments of environmental impact factors[113]. Shareholder Information - The largest shareholder, Huabang Life Health Co., Ltd., holds 567,308,354 shares, representing 46.28% of total shares[150]. - A total of 500,000,000 shares are pledged by Huabang Life Health Co., Ltd., with no shares under judicial freeze[154]. - The company has a total of 872,005,405 shares held by the top ten shareholders, which is 71.13% of total shares[151]. - The company has a total of 26,720 shareholders[146].
颖泰生物(833819) - 2023 Q1 - 季度财报
2023-04-25 16:00
Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY 70,545,123.01, a significant decrease of 72.89% compared to CNY 260,178,554.04 in the same period last year[9]. - Operating revenue for Q1 2023 was CNY 1,642,558,394.27, down 27.10% from CNY 2,253,210,484.92 year-on-year[9]. - The company reported a net loss of ¥33,207,066.22 for the first quarter of 2023, compared to a net profit of ¥289,666,777.48 in the same period of 2022, indicating a significant decline in profitability[87]. - Total operating revenue for Q1 2023 was ¥1,642,558,394.27, a decrease of 27.1% compared to ¥2,253,210,484.92 in Q1 2022[82]. - The company reported a total comprehensive income of ¥66,822,969.80 for Q1 2023, down from ¥267,299,941.53 in Q1 2022[84]. - The company's basic earnings per share (EPS) for Q1 2023 was -¥0.03, compared to ¥0.24 in Q1 2022, indicating a substantial drop in earnings per share[87]. Cash Flow and Assets - The net cash flow from operating activities decreased by 209.25%, resulting in a negative cash flow of CNY -187,566,831.47[11]. - Operating cash flow for the first quarter of 2023 was negative at ¥187,566,831.47, a stark contrast to a positive cash flow of ¥171,683,272.34 in the first quarter of 2022[91]. - The company’s cash and cash equivalents at the end of Q1 2023 stood at ¥1,019,782,862.67, down from ¥1,190,400,519.24 at the beginning of the quarter, resulting in a net decrease of ¥170,617,656.57[92]. - The company incurred total cash outflows from financing activities of ¥676,236,897.88 in Q1 2023, down from ¥961,371,205.40 in Q1 2022, reflecting a decrease of about 29.6%[92]. - The company’s total cash outflow from operating activities was ¥1,695,380,859.24 in Q1 2023, compared to ¥2,113,498,393.80 in Q1 2022, representing a decrease of about 19.7%[91]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,876[15]. - The largest shareholder, Huabang Life Health Co., Ltd., holds 45.82% of the shares, totaling 561,683,154 shares[17]. - The total shares held by major shareholders amounted to 872,984,281, representing 71.16% of the total shares[19]. - The company has a strict cash dividend policy in place, aiming to provide stable returns to investors over the next three years[40]. - The company has committed to a profit distribution policy that ensures at least 10% of the annual distributable profit is distributed in cash, with a cumulative cash distribution of no less than 30% of the average annual distributable profit over the last three years[65]. Operational Strategy - The company plans to adjust its operational strategies to maintain market share and ensure order fulfillment in response to increased competition and declining market demand[11]. - The company will improve internal controls to enhance fund management and prevent misappropriation of funds, thereby increasing profit margins[41]. - The company has outlined measures to enhance profitability and protect the rights of minority investors[38]. Compliance and Commitments - The company has timely fulfilled its obligations regarding external guarantees and related party transactions[24]. - The company commits to using raised funds effectively and will establish a special account for fund management to ensure compliance with regulations[38]. - The company will adhere to legal regulations regarding stock reduction and ensure timely and accurate information disclosure[35]. - The company ensures that all commitments made by its controlling shareholder and actual controller regarding the public offering are legally binding and will not be waived due to changes in their positions[45]. Asset Management - Total assets as of March 31, 2023, amounted to CNY 12,616,797,387.50, representing a 0.56% increase from the end of the previous year[9]. - The company's asset-liability ratio (consolidated) improved slightly to 52.44% from 52.72% at the end of the previous year[9]. - The total amount of restricted assets is approximately 2.39 billion yuan, accounting for 18.90% of total assets, primarily used for securing loans[70]. Research and Development - Research and development expenses for Q1 2023 were ¥49,743,368.63, a slight increase from ¥49,149,941.80 in Q1 2022[82].
颖泰生物:2022年年度报告业绩说明会预告公告
2023-04-17 08:10
证券代码:833819 证券简称:颖泰生物 公告编号:2023-025 北京颖泰嘉和生物科技股份有限公司 (一)会议召开时间:2023 年 4 月 20 日(星期四)15:00-17:00。 (二)会议召开地点 本次年度报告业绩说明会将采用网络方式召开,投资者可登录全 景网"投资者关系互动平台"(https://ir.p5w.net)参与本次年度 报告业绩说明会。 三、 参加人员 公司董事长: 王榕先生 公司董事会秘书: 刘晓亮先生 2022 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、误导 性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、 说明会类型 北京颖泰嘉和生物科技股份有限公司(以下简称"公司")于 2023 年 3 月 31 日在北京证券交易所指定信息披露平台 (http://www.bse.cn/)发布了《2022 年年度报告》(公告编号: 2023-013),为方便广大投资者更深入了解公司 2022 年经营业绩的具 体情况,加强与投资者的互动交流,公司拟召开 2022 年年度报告业 绩说明会。 二、 说明会 ...